Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05927948 · ClinicalTrials.gov registry record · NA

Evaluating the Safety and Efficacy of Laight®-Therapy Treatment in Subjects With Hidradenitis Suppurativa

A NA study, sponsored by Henry Ford Health System.

Completed
Registry status
NA
Development phase
10
Enrollment target

NCT05927948 is a NA study that has completed, run by Henry Ford Health System. The registered enrollment target is 10 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05927948, a NA study, has completed, sponsored by Henry Ford Health System.

COMPLETED
Registry status
NA
Development phase
10 participants
Enrollment target

Study Summary

Hidradenitis suppurativa (HS) is a debilitating and chronic condition characterized by recurrent episodes of inflammation associated with the formation of abscesses, inflammatory nodules, pain, and drainage ultimately culminating in the formation of scarring in moderate to severe disease. HS affects more women than men in a ratio of approximately 3:1, and onset of the disease is typically after puberty. The axillae, breasts, groin, buttocks, and lower abdomen are common intertriginous regions which are affected by HS, and significant impacts on quality of life are reported in the literature. The Hurley Staging system is commonly utilized to classify the severity of a patient\'s hidradenitis suppurativa. Stage 1 disease consists of one or more abscesses with no sinus tract formation or scarring. Stage 2 disease involves one or more widely separated recurrent abscesses, with formation of a sinus tract and/or scarring. Stage 3 involves multiple interconnected sinus tracts and/or abscesses throughout an anatomical area. Histologic studies of HS suggest that follicular hyperkeratosis and obstruction is the primary event in the pathogenesis. Subsequently, there is rupture of the follicular infundibulum and a resulting inflammatory cascade. Despite recurrent episodes of purulent drainage, bacteria do not appear to play a primary role in the pathogenesis. The traditional repertoire of treatment options for HS can be divided into medical and surgical options, however there is currently no cure for HS and treatments focus on symptomatic control. Medical treatments including topical and systemic antibiotics, hormonal agents, and biologic medications can successfully control symptoms however discontinuation of many of these is associated with relapses in disease symptoms. Conversely, surgical interventions such as traditional surgical excision performed in an operating room, or carbon dioxide laser excision performed under local anesthetic in an outpatient setting can in

Interventions

  • DEVICE Laight therapy, NICE V3.1 device

Trial Details

FieldValue
Enrollment Target 10 participants
Start Date 2019-11-04
Est. Completion 2021-12-01
Phase NA

Sponsor

Henry Ford Health System

234 total trials

What the Registry Record Tells You About NCT05927948

The ClinicalTrials.gov registry entry for NCT05927948 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Henry Ford Health System, which has 234 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Laight therapy, NICE V3.1 device is the first listed.

NCT05927948 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT05927948 about?

NCT05927948 is a clinical study titled "Evaluating the Safety and Efficacy of Laight®-Therapy Treatment in Subjects With Hidradenitis Suppurativa". Hidradenitis suppurativa (HS) is a debilitating and chronic condition characterized by recurrent episodes of inflammation associated with the formation of abscesses, inflammatory nodules, pain, and drainage ultimately culminating in the formation of scarring in moderate to severe disease. HS affects...

What is the current status of trial NCT05927948?

This trial is currently completed. It is a NA study. The enrollment target is 10 participants. The study started on 2019-11-04. Estimated completion is 2021-12-01.

What interventions are being tested in trial NCT05927948?

The interventions under investigation include: Laight therapy, NICE V3.1 device (DEVICE).

Who is sponsoring clinical trial NCT05927948?

This trial is sponsored by Henry Ford Health System, which has 234 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.